FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320914765> ?p ?o ?g. }

• W4320914765 abstract "Abstract Purpose Neoadjuvant chemotherapy (NAC) for triple negative (TN) and Her2 positive (HER2) breast cancers is supported by international guidelines as it can decrease extent of surgery, provide prognostic information and allow response-driven adjuvant therapies. Our goal was to describe practice patterns for patients with TN and HER2 breast cancer and identify factors associated with the receipt of NAC versus surgery as initial treatment. Methods A retrospective population-based cohort study of adult women diagnosed with stage I-III TN or HER2 breast cancer (2012-2019) in Ontario was completed using linked administrative datasets. The primary outcome was NAC as first treatment. The association between NAC and patient, tumour, and practice-related factors were examined using multivariable logistic regression models. Results Of 12,881 patients included, 22.9% (n = 2952) underwent NAC as first treatment. Patients who underwent NAC were more likely to be younger, have larger tumors, node positive disease and stage 3 disease. Of patients who underwent surgery first, 8.4% were seen by a medical oncologist prior to surgery. On multivariable analysis, increasing tumor size (T2 vs T1/T0: 2.63 (2.13 - 3.25)) and node positive (N1 vs N0: 3.60 (2.88 - 4.50)) disease were both associated increased odds of receiving NAC. Conclusion A considerable proportion of patients with TN and HER2 breast cancer do not receive NAC as first treatment. Of those, most were not assessed by both a surgeon and medical oncologist prior to initiating therapy. This points towards potential gaps in multidisciplinary assessment and disparities in receipt of guideline-concordant care." @default.
• W4320914765 created "2023-02-16" @default.
• W4320914765 creator A5008281650 @default.
• W4320914765 creator A5018442509 @default.
• W4320914765 creator A5030239845 @default.
• W4320914765 creator A5037269259 @default.
• W4320914765 creator A5039283573 @default.
• W4320914765 creator A5057024351 @default.
• W4320914765 creator A5057770795 @default.
• W4320914765 creator A5058397486 @default.
• W4320914765 creator A5065891328 @default.
• W4320914765 date "2023-02-15" @default.
• W4320914765 modified "2023-10-12" @default.
• W4320914765 title "Neoadjuvant chemotherapy for triple negative and Her2+ve breast cancer: striving for the standard of care" @default.
• W4320914765 cites W1555003755 @default.
• W4320914765 cites W1966064734 @default.
• W4320914765 cites W2049491523 @default.
• W4320914765 cites W2057780602 @default.
• W4320914765 cites W2101831741 @default.
• W4320914765 cites W2147415463 @default.
• W4320914765 cites W2162760540 @default.
• W4320914765 cites W2163278718 @default.
• W4320914765 cites W2164774797 @default.
• W4320914765 cites W2172114428 @default.
• W4320914765 cites W2461634528 @default.
• W4320914765 cites W2502671370 @default.
• W4320914765 cites W2511059339 @default.
• W4320914765 cites W2533041332 @default.
• W4320914765 cites W2618058692 @default.
• W4320914765 cites W2759978833 @default.
• W4320914765 cites W2801045744 @default.
• W4320914765 cites W2897407370 @default.
• W4320914765 cites W2902218997 @default.
• W4320914765 cites W2946325513 @default.
• W4320914765 cites W2981498497 @default.
• W4320914765 cites W2981751082 @default.
• W4320914765 cites W3031404507 @default.
• W4320914765 cites W3082718392 @default.
• W4320914765 cites W3093782821 @default.
• W4320914765 cites W3110827616 @default.
• W4320914765 cites W3116588722 @default.
• W4320914765 cites W3122861570 @default.
• W4320914765 cites W3128123841 @default.
• W4320914765 cites W4211123279 @default.
• W4320914765 cites W4214625336 @default.
• W4320914765 doi "https://doi.org/10.21203/rs.3.rs-2521809/v1" @default.
• W4320914765 hasPublicationYear "2023" @default.
• W4320914765 type Work @default.
• W4320914765 citedByCount "0" @default.
• W4320914765 crossrefType "posted-content" @default.
• W4320914765 hasAuthorship W4320914765A5008281650 @default.
• W4320914765 hasAuthorship W4320914765A5018442509 @default.
• W4320914765 hasAuthorship W4320914765A5030239845 @default.
• W4320914765 hasAuthorship W4320914765A5037269259 @default.
• W4320914765 hasAuthorship W4320914765A5039283573 @default.
• W4320914765 hasAuthorship W4320914765A5057024351 @default.
• W4320914765 hasAuthorship W4320914765A5057770795 @default.
• W4320914765 hasAuthorship W4320914765A5058397486 @default.
• W4320914765 hasAuthorship W4320914765A5065891328 @default.
• W4320914765 hasBestOaLocation W43209147651 @default.
• W4320914765 hasConcept C121608353 @default.
• W4320914765 hasConcept C126322002 @default.
• W4320914765 hasConcept C143998085 @default.
• W4320914765 hasConcept C146357865 @default.
• W4320914765 hasConcept C151730666 @default.
• W4320914765 hasConcept C151956035 @default.
• W4320914765 hasConcept C156957248 @default.
• W4320914765 hasConcept C167135981 @default.
• W4320914765 hasConcept C2776694085 @default.
• W4320914765 hasConcept C2777757722 @default.
• W4320914765 hasConcept C2778292576 @default.
• W4320914765 hasConcept C2779134260 @default.
• W4320914765 hasConcept C2779786085 @default.
• W4320914765 hasConcept C2780110267 @default.
• W4320914765 hasConcept C2908647359 @default.
• W4320914765 hasConcept C530470458 @default.
• W4320914765 hasConcept C71924100 @default.
• W4320914765 hasConcept C72563966 @default.
• W4320914765 hasConcept C86803240 @default.
• W4320914765 hasConcept C99454951 @default.
• W4320914765 hasConceptScore W4320914765C121608353 @default.
• W4320914765 hasConceptScore W4320914765C126322002 @default.
• W4320914765 hasConceptScore W4320914765C143998085 @default.
• W4320914765 hasConceptScore W4320914765C146357865 @default.
• W4320914765 hasConceptScore W4320914765C151730666 @default.
• W4320914765 hasConceptScore W4320914765C151956035 @default.
• W4320914765 hasConceptScore W4320914765C156957248 @default.
• W4320914765 hasConceptScore W4320914765C167135981 @default.
• W4320914765 hasConceptScore W4320914765C2776694085 @default.
• W4320914765 hasConceptScore W4320914765C2777757722 @default.
• W4320914765 hasConceptScore W4320914765C2778292576 @default.
• W4320914765 hasConceptScore W4320914765C2779134260 @default.
• W4320914765 hasConceptScore W4320914765C2779786085 @default.
• W4320914765 hasConceptScore W4320914765C2780110267 @default.
• W4320914765 hasConceptScore W4320914765C2908647359 @default.
• W4320914765 hasConceptScore W4320914765C530470458 @default.
• W4320914765 hasConceptScore W4320914765C71924100 @default.
• W4320914765 hasConceptScore W4320914765C72563966 @default.
• W4320914765 hasConceptScore W4320914765C86803240 @default.
• W4320914765 hasConceptScore W4320914765C99454951 @default.

• next